Latest Research
All publications from the Cancer3.AI database, newest first.
SOX-2 and EZH-2 Expression in Primary Epithelial Malignant Salivary Gland Tumors.
Costin CA, et al
Researchers at 'Sf. Spiridon' County Hospital in Iași, Romania, examined the expression of two molecular markers — SOX-2 and EZH-2 — in 104 patients with primary epithelial malignant salivary gland tumors over a 15-year period to evaluate their diagnostic and prognostic value. High SOX-2 expression was significantly associated with lymphatic invasion, tumor stage, histological tumor type, and tumor grade, while high EZH-2 expression correlated with perineural invasion, vascular invasion, lymphatic invasion, tumor grade, and pathological extranodal extension. Both markers were independently linked to significantly reduced overall survival, with high SOX-2 and EZH-2 expression each more than doubling the risk of a poor survival outcome in Cox regression analysis. These findings indicate that SOX-2 and EZH-2 may function as reliable biomarkers of aggressive tumor behavior and unfavorable prognosis in malignant salivary gland cancers, and highlight them as promising candidates for precision-targeted therapeutic strategies in this heterogeneous and challenging group of malignancies.
Medical sciences (Basel, Switzerland)
Source →Corrigendum to "Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer" [Radiother. Oncol. 216 (2026) 111385].
Sittiwong W, et al
This publication is a corrigendum, meaning it is a formal correction to a previously published study that examined long-term outcomes of high-dose-rate (HDR) brachytherapy monotherapy using a single fraction of 19 Gy for localized prostate cancer. The original multicentre study assessed the safety and effectiveness of this highly concentrated, single-session radiation treatment approach in men with prostate cancer confined to the gland. Corrigenda are important in scientific publishing as they ensure the accuracy of the medical record by correcting errors in data, figures, or text that could otherwise influence clinical decision-making. Clinicians and researchers relying on the original findings should consult this correction to ensure they are working with the most accurate version of the study's results.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Source →Association of blood biomarkers with p53 gene expression in male infertility.
Ramachandran Krishnakumary A, et al
A new case-control study from Kerala, India, examined the relationship between the tumor-suppressor gene p53 and blood biomarkers — prostate-specific antigen (PSA), sialic acid, and vitamin C — in 150 infertile men compared with 150 fertile controls. Researchers found that infertile men had significantly higher p53 gene activity and PSA levels, while their antioxidant markers (sialic acid and vitamin C) were notably depleted. Statistical modeling revealed that low vitamin C was a strong negative predictor of p53 expression and elevated PSA was a positive predictor, suggesting that oxidative stress may drive genomic surveillance pathways in these patients. Importantly, the authors emphasize that these molecular changes reflect cellular stress responses rather than signs of cancer, providing reassurance while highlighting the biological burden infertility can place on male reproductive cells. These findings may help clinicians better understand the underlying molecular mechanisms of male infertility and point toward antioxidant supplementation as a potential therapeutic avenue worth investigating.
Hormone molecular biology and clinical investigation
Source →Effect of TU-100 on Colorectal Liver Metastasis in Mouse Model of MASH.
Yamada S, et al
Researchers investigated whether the traditional Japanese herbal medicine Daikenchuto (TU-100) could reduce colorectal liver metastasis in mice with metabolic dysfunction-associated steatohepatitis (MASH), a liver condition increasingly linked to enhanced cancer spread. Using a mouse model fed a high-fat Western diet, the team administered TU-100 and then introduced colon cancer cells directly into the bloodstream to simulate metastatic disease. Mice receiving TU-100 showed significantly less liver fat accumulation and developed smaller liver tumors compared to untreated mice on the same diet. The treatment also suppressed liver expression of two key molecular markers — serum amyloid A1 and tissue inhibitor of matrix metalloproteinases 1 — which are associated with inflammation and tumor-promoting tissue remodeling. These findings suggest that TU-100 may help protect the liver from becoming a favorable environment for metastatic colorectal cancer, offering a potential complementary strategy for patients with both MASH and colorectal cancer.
The Journal of surgical research
Source →Ferroptosis as an approach to leverage cancer metabolism.
Jin J, et al
Researchers have published a comprehensive review examining ferroptosis — a form of regulated cell death driven by iron-dependent oxidation of membrane fats — and its potential as a target for cancer therapy. The review explores how cancer cells frequently alter key metabolic pathways related to iron handling, lipid synthesis, and antioxidant defense, making them potentially vulnerable to this specific type of cell death. The authors highlight that the unique metabolic landscape of tumors may create exploitable weaknesses, where triggering ferroptosis could selectively kill cancer cells while sparing healthy tissue. These insights point toward promising new therapeutic strategies that leverage cancer's own metabolic abnormalities against it, offering hope for patients whose cancers are resistant to conventional treatments.
Trends in cell biology
Source →